Research programme: mannose receptor-targeted diagnostic and therapeutic agents - Macrophage Therapeutics

Drug Profile

Research programme: mannose receptor-targeted diagnostic and therapeutic agents - Macrophage Therapeutics

Alternative Names: CD206 receptor-targeted diagnostics - Navidea Biopharmaceuticals; Cy3-Manocept; Cy3-Manocept-doxorubicin; Cy3-tilmanocept; Manocept™-derived diagnostic agents - Navidea Biopharmaceuticals; MT 1000; MT 1001; MT 2000; MT 2001; MT 2002; MT-1002

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Navidea Biopharmaceuticals
  • Developer Macrophage Therapeutics; Navidea Biopharmaceuticals; University of California at San Francisco; Unknown
  • Class Diagnostic agents; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Mannose receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Cardiovascular disorders; CNS disorders; Infections; Kaposi's sarcoma; Non-alcoholic fatty liver disease; Rheumatoid arthritis; Tuberculosis
  • Research Crohn's disease; Inflammatory bowel diseases

Most Recent Events

  • 29 Mar 2017 Early research in Crohn's disease in USA (unspecified route)
  • 29 Mar 2017 Early research in Inflammatory bowel disease in USA (unspecified route)
  • 26 May 2016 Navidea Biopharmaceuticals receives SBIR grant from National Institutes of Health’s (NIH) National Cancer Institute (NCI) for Manocept™-based immunotargeted treatment in Kaposi’s Sarcoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top